Eric Longenhagen and I posted a too-early ranking of the top 2016 MLB draft prospects, one that highlights the lack of a clear #1 overall prospect.
And now, the links…
- Glenn Greenwald destroyed CNN for suspending reporter Elise Labott for two weeks for a rather innocuous (my opinion) tweet on the Syrian refugee topic. Greenwald even went on CNN to rip them apart for their fearmongering and mishandling of Labott, as covered here by Erik Wemple, whose initial complaint of Labott’s “bias” in her tweet seems to have sparked the suspension. (Wemple has said he opposes such suspensions, but I don’t see why he singled out Labott, a relatively unknown female reporter, among the various more serious breaches of ethics Greenwald listed.)
- Alabama Congressman Mo Brooks says Syrian refugees are just looking for a “paid vacation.”
- Is the west’s reaction to the Paris terror attacks the war that ISIS wants?
- The young Iraqis who are presumably risking their lives promoted evolutionary theory and rational thinking.
- A great longread on so-called “inauthentic” ethnic cuisine as practiced by Asian-American chefs like Danny Bowien, Dale Talde, and David Chang. Authenticity is great, but isn’t de facto superior to inauthentic food made well.
- The Guardian weighs in on fad diets that are often light on science, asking what constitutes “healthy eating?”
- Aziz Ansari appeared on NPR’s The Hidden Brain podcast to discuss findings from his book on love and dating, co-authored with a sociologist, called Modern Romance.
- Via a reader, a story from June in Slate that describes aquafaba, the possible vegan replacement for egg whites. It’s actually just the brining liquid found in canned chickpeas, and for reasons not yet understood, its protein structure can create a stable foam just like the albumin from chicken eggs.
- Remember that hedge fund douchebag who bought the rights to a decades-old drug and raised the price fifty-fold, then reversed that decision under public pressure? Yeah, well, they reversed that reversal. It’s a clear situation where the free market – of which I’m a rather ardent supporter – fails, because the market for the drug is so small (the NY Times says that there were only 8821 prescriptions for it in 2014) that it likely wouldn’t support the creation of a competitor due to the high regulatory costs. The only solution I see would be for the FDA to “fast track” a generic alternative, assuming a manufacturer could be found – or, unfortunately, for the federal government to mandate a price cap.